Health Care · Medical Devices

Bioventus Inc. BVS

$13.19+0.07 (+0.53%)delayed quote · as of 2026-07-30 13:38 UTC

Open BVS in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$893.6M

Previous close

$13.12

Volume

20K

52-week range

$5.81 – $13.55

Verdictconfidence 88% · high

Strong across every dimension we score.

4 of 5 dimensions score well. Momentum not scored — not enough data.

Value804/5 checks

Growth804/5 checks

Quality1005/5 checks

Health804/5 checks

Momentum—2/2 checks

Fair-value estimate $23.21 per share (2-stage FCF · individual beta · 10Y Rf 4.6%) — the price sits 43% below it.

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

32.2

P/E FWD

14.5

EV/EBITDA TTM

13.6

PEG

0.66

FCF yield TTM

11.3%

Growth

Revenue 3y

+3.5%/yr

Revenue YoY

−0.9%

Expected EPS

+121.5%

Quality

Piotroski F

9 / 9

ROIC

12.5%

Gross margin

68.3%

Health

Altman Z

1.78

Current ratio

1.70

Debt/equity

1.60

Momentum

vs 50-day

—

vs 200-day

—

52-wk range

95%

FY 2025: revenue $568.1M · net income $22.7M · free cash flow $72.1M (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-30 13:38 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading BVS’s filed statements…

Continue with BVS in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.